| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
N/A |
| Shares
Out: |
262,940,000 |
| Market
Cap: |
3.81(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0002 - $0.399 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sorrento Therapeutics is a clinical stage and commercial biopharmaceutical company that delivers therapies to address unmet medical needs. Co. has programs assessing the use of its technologies and products in autoimmune, inflammatory, viral and neurodegenerative diseases. Co.'s segments are: Sorrento Therapeutics, which includes Sofusa®, a drug delivery technology that delivers biologics into the lymphatic system, and resiniferatoxin, a non-opioid-based neurotoxin in clinical trials for late stage cancer pain and moderate to severe osteoarthritis of the knee pain; and Scilex, which includes ZTlido, a lidocaine topical system for the relief of pain associated with post-herpetic neuralgia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
199,998 |
| Total Buy Value |
$0 |
$0 |
$0 |
$404,332 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scifres Donald R |
10% Owner |
– – • |
2011-12-29 |
5/A |
B |
$0.16 |
$2,000,000 |
I/I |
12,500,000 |
38,844,714 |
|
- |
|
| Scifres Donald R |
10% Owner |
– – • |
2011-12-29 |
5 |
B |
$0.16 |
$2,000,000 |
I/I |
12,500,000 |
48,658,594 |
|
- |
|
| Scifres Donald R |
10% Owner |
– – • |
2011-08-28 |
5/A |
GD |
$0.00 |
$0 |
I/I |
9,813,880 |
26,344,714 |
|
- |
|
| Afting Ernst-Gunter |
Director |
– • – |
2010-12-21 |
4 |
B |
$0.14 |
$50,400 |
D/D |
360,000 |
917,930 |
2.39 |
- |
|
| Ji Henry |
Chief Scientific Officer & Sec |
• • • |
2010-11-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
5,096,865 |
43,754,032 |
|
- |
|
| Ji Henry |
Chief Scientific Officer & Sec |
• • • |
2010-11-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,096,865 |
0 |
|
- |
|
| Ji Henry |
Chief Scientific Officer & Sec |
• • • |
2010-05-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
38,657,167 |
38,657,167 |
|
- |
|
| Ji Henry |
Chief Scientific Officer & Sec |
• • • |
2010-05-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
38,657,167 |
5,096,865 |
|
- |
|
| Ji Henry |
Chief Scientific Officer & Sec |
• • • |
2010-04-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,000,000 |
43,754,032 |
|
- |
|
| Zaniboni Steve |
Director |
– • • |
2010-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,484,329 |
|
- |
|
| Hsiao Jane Ph D |
Director |
– • – |
2010-01-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,231,719 |
|
- |
|
| Zaniboni Steve |
10% Owner |
– – • |
2009-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,484,329 |
|
- |
|
| Freedman S. James |
Director |
– • – |
2009-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
111,586 |
|
- |
|
| Ji Henry |
Chief Sci. Officer & Secretary |
• • – |
2009-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,785,375 |
|
- |
|
| Shuster Lewis |
Director |
– • – |
2009-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
669,516 |
|
- |
|
| Afting Ernst-Gunter |
Director |
– • – |
2009-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
557,930 |
|
- |
|
| Opko Health, Inc. |
10% Owner |
– – • |
2009-09-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
59,015,257 |
|
- |
|
| Ji Henry |
Chief Sci. Officer & Secretary |
• • • |
2009-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
50,968,657 |
52,754,032 |
|
- |
|
| Schuh Antonius |
Chief Executive Officer |
• • • |
2009-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
25,484,329 |
25,484,329 |
|
- |
|
| Halpryn Glenn L |
Director |
– • – |
2009-09-18 |
4 |
B |
$0.04 |
$804,847 |
I/I |
17,965,330 |
781,102 |
2.1 |
- |
|
| Stein Ronald M |
Director |
– • – |
2008-07-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,693,472 |
|
- |
|
| Weisberg Alan Jay |
CFOOfficer |
• • – |
2008-07-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
785,925 |
|
- |
|
| Halpryn Glenn L |
CEO and PresidentOfficer |
• • – |
2008-07-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,641,737 |
|
- |
|
| Silver Noah M |
VP, Secretary and TreasurerOff |
• • – |
2008-07-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,054,666 |
|
- |
|
| Keating Kevin R |
See Remarks |
– – – |
2008-07-07 |
4 |
S |
$0.01 |
$21,440 |
D/D |
(1,600,000) |
0 |
|
- |
|
158 Records found
|
|
Page 6 of 7 |
|
|
